Abstract：Objective To explore the effect of Dapagliflozin on islet function in type 2 diabetic mellitus (T2DM) patients with obesity and poor glucose control. Methods A total of 73 T2DM patients with obesity and poor glucose control treated in Huai’an Cancer Hospital of Jiangsu Province from June 2019 to March 2021 were selected as the research objects. According to the random number table method, they were divided into experimental group (37 cases) and control group (36 cases). The control group was treated with Risenatide, experimental group was treated with Dapagliflozin combined with Risenatide. The insulin resistance index (HOMA-IR), islet β-cell function index (HOMA-β), fasting blood glucose and 2-h postprandial blood glucose, glycosylated hemoglobin (HbA1c), body mass index (BMI), and body fat rate were compared between two groups before treatment and six months after treatment; the time to blood glucose target between two groups were compared; the adverse reactions during treatment were recorded. Results After treatment, HOMA-IR, fasting blood glucose, 2-h postprandial blood glucose, HbA1c, BMI, and body fat rate in two groups were lower than those before treatment, and those in the experimental group were lower than those in control group (P ＜ 0.05). HOMA-β in two groups was higher than that before treatment, and that in experimental group was higher than that in control group (P ＜ 0.05). There was no significant difference in the incidence of total adverse reactions between two groups (P ＞ 0.05). Conclusion Dapagliflozin in the treatment of T2DM patients with obesity and poor glucose control can effectively improve the islet function, regulate the blood glucose level, improve the degree of obesity and have good safety.
周洁 吴新华 严妍 时雯 朱平▲. 达格列净对血糖控制不佳的2型糖尿病伴肥胖患者胰岛功能的影响[J]. 中国医药导报, 2022, 19(33): 75-78.
ZHOU Jie WU Xinhua YAN Yan SHI Wen ZHU Ping▲. Effect of Dapagliflozin on islet function in type 2 diabetes mellitus with obesity and poor glucose control. 中国医药导报, 2022, 19(33): 75-78.
京公网安备 11010502046598号